Nightingale Health Oyj (NHLTY)
| Market Cap | 129.06M -20.6% |
| Revenue (ttm) | 6.29M +17.2% |
| Net Income | -21.10M |
| EPS | -0.34 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 2.140 |
| Previous Close | 1.520 |
| Day's Range | 2.140 - 2.140 |
| 52-Week Range | 0.916 - 2.550 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 9, 2027 |
About Nightingale Health Oyj
Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, Europe, the Middle East, Africa, AMER, and the Asia-Pacific. The company’s Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely, as well as multiomics analysis services. It provides its services to research programs, universities, and healthcare providers. The company has a collaboration with Personalised Health... [Read more]
Financial Performance
In fiscal year 2026, Nightingale Health Oyj's revenue was 5.50 million, an increase of 17.24% compared to the previous year's 4.69 million. Losses were -18.47 million, 0.06% more than in 2025.
Financial numbers in EUR Financial StatementsNews
Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
FREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX: NHLTY, NGHLF) today announc...
Nightingale Health Oyj Earnings Call Transcript: H2 2026
Revenue grew 17% year-over-year to €5.5 million, below target due to a project delay, but the company aims to double revenue to €10 million this year. Global expansion, improved product-market fit, and a strong sales pipeline support this outlook.
Nightingale Health Oyj Quarterly report: H2 2026
Nightingale Health Oyj has published its H2 2026 quarterly earnings report on September 16, 2026.
Nightingale Health Oyj Slides: H2 2026
Nightingale Health Oyj has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 16, 2026.
Nightingale Health Oyj Annual report: H2 2026
Nightingale Health Oyj has published its H2 2026 annual report on September 16, 2026.
Nightingale Health Oyj Earnings Call Transcript: H1 2026
Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.
Nightingale Health Oyj Quarterly report: H1 2026
Nightingale Health Oyj has published its H1 2026 quarterly earnings report on March 5, 2026.
Nightingale Health Oyj Slides: H1 2026
Nightingale Health Oyj has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 5, 2026.